A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
ASCO 2013 provides upside potential !
This pick was made because its below the 50day moving average as of April 10th.The whole list I perused through below 50dmva for 4/10/13 were;AMZN,SIRI,PRAN,PCYC,CNQR,PCLN,CRM,LULU,CVLT,NFLX,ULTI,CTXSThese tickers were picked from my tracking universe of the following tickers:CCI,AMZN,SIRI,LMT,PNRA,SBAC,RPRX,PRAN,MDVN,VZ,ALXN,PCYC,CNQR,INFI,VRTX,PCLN,CRM,LULU,CVLT,NFLX,OPEN,GMCR,N,CAR,REGN,T,SBUX,MO,ULTI,MAR,EQIX,CTXS,CLH,BLLThis was supposed to be a simple tracking blog post rather than a pitch but as a new player, it takes a couple of days to be approved for blog posting...oh well. Hopefully I remember to look back at these pitches.
Great company with lots of cash that has been shooting up for a long time. I bought on the dip today and I'm buying in my motley fool caps as well.
They're finally profitable and they got profitable in a big way.
Price levels are out of whack with fundamentals
Game changing medication for several forms of leukemia, including CLL, about to be approved by FDA.
1 star caps rating? another reason why we should not rely on the so called TMF pros. Good lesson of humility for some of them.Immunokinases are a hot target these days, as hot as the multibillion market opportunity of hematological cancers. Of course, any safety/efficacy issues and the stock will tank hard
Parabolic technicals, stupidly overvalued fundamentals
Why is this stock valued as if all of the company's drugs have been approved? Ridiculous valuation for an early stage biotech!
Eegads... don't think I've ever seen so many highly-ranked fools with -1000+ points associated as with this stock. Maybe shipping or solar, back in the day. Anyway, underperform...
one anomolous quarter is pumping up their earnings and stock price. None of their drugs have even started stage 3 trials yet. Stock spammers love them.
Ibrutinib has potential, but risk reward is too unfavorable after the run up.
went to 300% increase for potofeille.
high relative strenght
I think pcyc will hit $50.00 in 5years.
What happens to a shooting star when it has no FDA approvals on products. It will need more cash to burn...
Skyrocketed based on expectations; no tangible results & more lofty expectations based on today's valuation compared to most other biotechs
Strictly going off the genius Baker Brothers buying the stock. The fundamentals of this company look like any other infant-stage biotech... awful.
For details about CAPS-UK, and the conditions you agree to be bound by, please see our
Terms and Conditions.
© Copyright 1998-2013, The Motley Fool Limited. All rights reserved. This material is for personal use only.
The Motley Fool, Fool, and the "Fool" logo are registered trademarks of The Motley Fool, Holdings, Inc.
Place of Reg: England & Wales. Company Reg No: 3736872. VAT Reg No: 945 6990 68. Registered Office: 5th Floor, 60 Charlotte Street London W1T 2NU.
This page brought to you by USEQ\WEB21.